Halozyme Announces argenx's VYDURA with ENHANZE® was …
Dec 30, 2024 · Having touched more than 800,000 patient lives in post-marketing use in nine commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE ® technology to leading ...
Halozyme Announces argenx's VYDURA with ENHANZE® was …
Dec 30, 2024 · Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated with Halozyme's ENHANZE® drug ...
Halozyme Announces argenx's VYDURA with ENHANZE® was …
SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is...
Halozyme Announces argenx's VYDURA with ENHANZE® was …
SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is...
News - Halozyme
2 days ago · Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications 12/30/2024
Halozyme Therapeutics (HALO) Announces argenx's VYDURA with ENHANZE …
Dec 30, 2024 · Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated with Halozyme's ENHANZE ® drug...
Halozyme Announces Expansion of Global Collaboration and …
Oct 3, 2024 · Four new targets nominated for total of six nominated targets, including FcRn (VYVGART ® Hytrulo), for ENHANZE ® drug delivery technology Halozyme to receive total upfront payment of $30 million...
Halozyme Announces Positive Clinical Data of its High-Volume …
Oct 16, 2023 · Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic product co-formulated with its ENHANZE® drug delivery technology, in approximately 30 seconds.
Halozyme Announces FDA Approval of Roche's Tecentriq …
SAN DIEGO, Sept. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received U.S. Food and Drug Administration (FDA) approval for Tecentriq...
Halozyme Announces FDA Approval of Bristol Myers Squibb's …
Dec 30, 2024 · "We are pleased Opdivo Qvantig, which is co-formulated with our ENHANZE drug delivery technology, is now FDA-approved as the first and only subcutaneously administered PD-1 inhibitor in the...